A novel three-dose regimen of daclizumab
โ
W. Kenneth Washburn; Lewis W. Teperman; Thomas G. Heffron; David D. Douglas; Ste
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 161 KB
This study evaluated the pharmacokinetics and pharmacodynamics of a novel 3-dose regimen of daclizumab in de novo hepatitis C liver transplant recipients. In 30 of 156 recipients receiving daclizumab, mycophenolate mofetil, tacrolimus, and no steroids (Arm 3 of Hep C 3 Liver Study), daclizumab (2, 2